Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study.

IF 3.4 4区医学 Q2 RHEUMATOLOGY

Clinical and experimental rheumatology Pub Date : 2024-09-24 DOI:10.55563/clinexprheumatol/jmpuxa

Hanxiao You, Chengyin Lv, Lingxiao Xu, Lei Wang, Ting Liu, Fenghong Yuan, Wei Yan, Hua Wei, Jiajia Wang, Deqian Meng, Wenfeng Tan

{"title":"Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study.","authors":"Hanxiao You, Chengyin Lv, Lingxiao Xu, Lei Wang, Ting Liu, Fenghong Yuan, Wei Yan, Hua Wei, Jiajia Wang, Deqian Meng, Wenfeng Tan","doi":"10.55563/clinexprheumatol/jmpuxa","DOIUrl":null,"url":null,"abstract":"Objectives: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) is frequently linked with interstitial lung disease (ILD), especially the rapidly progressive ILD (RP-ILD). We conduct this research to evaluate the efficacy and safety of triple-combination (triple-combo) therapy consisting of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide in treating MDA5+ DM patients with ILD.Methods: A multicentre longitudinal cohort study involving 115 MDA5+ DM patients from the Nanjing Medical University Myositis Associated ILD (NMMI) cohort was conducted between January 2019 and November 2022. Patients were categorised into triple-combo and non-triple therapy groups, and their outcomes were assessed.Results: Contrary to expectations, triple-combo therapy did not improve the prognosis for MDA5+ DM patients but was linked to increased mortality rates, especially among those at high risk for RP-ILD.Conclusions: Our study suggests that triple-combo therapy might not be effective in improving prognosis in MDA5+ DM patients. Further research is needed to establish safer and more effective treatment modalities for this patient population.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/jmpuxa","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) is frequently linked with interstitial lung disease (ILD), especially the rapidly progressive ILD (RP-ILD). We conduct this research to evaluate the efficacy and safety of triple-combination (triple-combo) therapy consisting of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide in treating MDA5+ DM patients with ILD.

Methods: A multicentre longitudinal cohort study involving 115 MDA5+ DM patients from the Nanjing Medical University Myositis Associated ILD (NMMI) cohort was conducted between January 2019 and November 2022. Patients were categorised into triple-combo and non-triple therapy groups, and their outcomes were assessed.

Results: Contrary to expectations, triple-combo therapy did not improve the prognosis for MDA5+ DM patients but was linked to increased mortality rates, especially among those at high risk for RP-ILD.

Conclusions: Our study suggests that triple-combo therapy might not be effective in improving prognosis in MDA5+ DM patients. Further research is needed to establish safer and more effective treatment modalities for this patient population.

查看原文本刊更多论文

三联疗法并不能改善抗MDA5阳性皮肌炎患者的预后：一项多中心纵向队列研究。

目的：抗黑色素瘤分化相关基因5阳性皮肌炎（MDA5+ DM）经常与间质性肺病（ILD）有关，尤其是快速进展性间质性肺病（RP-ILD）。我们开展这项研究的目的是评估由大剂量皮质类固醇、他克莫司和静脉注射环磷酰胺组成的三联疗法（三联疗法）治疗MDA5+ DM ILD患者的疗效和安全性：在2019年1月至2022年11月期间开展了一项多中心纵向队列研究，涉及南京医科大学肌炎相关ILD（NMMI）队列中的115名MDA5+ DM患者。研究将患者分为三联疗法组和非三联疗法组，并对其疗效进行了评估：结果：与预期相反，三联疗法并没有改善MDA5+ DM患者的预后，反而增加了死亡率，尤其是RP-ILD高危患者：我们的研究表明，三联疗法可能无法有效改善MDA5+ DM患者的预后。我们的研究表明，三联疗法可能无法有效改善 MDA5+ DM 患者的预后，需要进一步研究，为这一患者群体建立更安全、更有效的治疗模式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental rheumatology 医学-风湿病学

CiteScore

6.10

自引率

18.90%

发文量

377

审稿时长

3-6 weeks

期刊介绍： Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.